MCID: ADN012
MIFTS: 45

Adenocarcinoma in Situ malady

Cancer diseases category

Aliases & Classifications for Adenocarcinoma in Situ

About this section

Aliases & Descriptions for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 8 10 61


Classifications:



External Ids:

Disease Ontology8 DOID:4943
SNOMED-CT56 51642000
NCIt39 C4123

Summaries for Adenocarcinoma in Situ

About this section
MalaCards based summary: Adenocarcinoma in Situ is related to cervical adenocarcinoma and colon adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDX2 (caudal type homeobox 2), and among its related pathways are TP53 network and EGFR Transactivation by Gastrin. The compounds temozolomide and anastrozole have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and testes, and related mouse phenotypes are pigmentation and vision/eye.

Related Diseases for Adenocarcinoma in Situ

About this section

Diseases in the Adenocarcinoma family:

adenocarcinoma in situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 146)
idRelated DiseaseScoreTop Affiliating Genes
1cervical adenocarcinoma30.6CDKN2A, CDKN1A, CDX2, KRT20, IFI27, CEACAM7
2colon adenocarcinoma30.2CDKN1A, KRT20, KRAS, CEACAM7, CEACAM5
3lung cancer29.9EGFR, CDKN2A, CDKN1A, KRAS, ERBB2
4papillary carcinoma29.7KRT20, ERBB2, IFI27, ESR1, PAX8, PGR
5adenoma29.5CDKN2A, CDKN1A, CDX2, KRT20, KRAS, IFI27
6adenocarcinoma28.8EGFR, WT1, CDKN2A, CDKN1A, CDX2, KRT20
7retinoblastoma28.5EGFR, WT1, CDKN2A, CDKN1A, KRAS, ERBB2
8cervicitis11.0
9endocervicitis10.8
10endocervical adenocarcinoma10.7
11multicystic dysplastic kidney10.6PAX2
12cystadenocarcinoma10.5CEACAM5
13inverted papilloma10.5KRT20
14pseudomyxoma peritonei10.5CDX2, KRT20
15metanephric adenoma10.5WT1
16cervical intraepithelial neoplasia10.5
17bladder adenocarcinoma10.5CDX2, KRT20
18secretory meningioma10.5VIM
19mucinous cystadenocarcinoma10.5KRT20, CEACAM7
20nephrogenic adenoma10.4PAX8, PAX2
21diffuse mesangial sclerosis10.4WT1, PAX2
22cerebral meningioma10.4PGR
23ovarian brenner tumor10.4WT1, KRT20
24cervix endometriosis10.4TOP2A, MCM2
25signet ring cell adenocarcinoma10.4KRT20, CEACAM5
26rectal neoplasm10.4IFI27, CEACAM5
27denys-drash syndrome10.4WT1, PAX2
28microinvasive gastric cancer10.4CDX2, CEACAM5
29cystadenoma10.4KRAS
30focal segmental glomerulosclerosis10.4WT1, IFI27, PAX2
31gastrointestinal carcinoma10.4KRT20, CEACAM7, CEACAM5
32gallbladder cancer10.4CDX2, IFI27, CEACAM5
33neuroendocrine tumor10.3CDX2, KRT20, CEACAM5
34malignant pleural mesothelioma10.3WT1, CEACAM7, CEACAM5
35mucinous adenocarcinoma10.3
36papillary adenocarcinoma10.3
37adenomatoid tumor10.3WT1, VIM
38sertoli-leydig cell tumor10.3WT1, PGR
39thyroid carcinoma, papillary10.3IFI27, TOP2A, PAX8
40bladder transitional cell carcinoma10.3KRT20, IFI27
41li-fraumeni syndrome10.3CDKN2A, CDKN1A
42merkel cell carcinoma10.3KRT20, TOP2A
43barrett esophagus/esophageal adenocarcinoma10.3CDKN2A, CDX2, KRT20, MCM2
44adenosarcoma10.2ESR1, PGR
45oxyphilic adenoma10.2KRT20, VIM, PAX2
46neuroendocrine carcinoma10.2
47endometrial adenocarcinoma10.2
48endometriosis10.2
49hidradenoma10.2
50vaginitis10.2

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to adenocarcinoma in situ

Symptoms for Adenocarcinoma in Situ

About this section

Drugs & Therapeutics for Adenocarcinoma in Situ

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Cervarix13 38 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009
FDA Label: -
Malady that Drug Treats: prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:13 -
DrugBank Targets: -
Mechanism of Action:13 
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
2
Gardasil13 38 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006
FDA Label: Gardasil
Malady that Drug Treats: Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:13 GARDASIL is a vaccine indicated in girls and women 9 through 26; years of age for the prevention of the following diseases caused by; Human Papillomavirus (HPV) types included in the vaccine:; Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16; and 18 (1.1); Genital warts (condyloma acuminata) caused by HPV types 6 and; 11 (1.1); And the following precancerous or dysplastic lesions caused by HPV; types 6, 11, 16, and 18:; Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical; adenocarcinoma in situ (AIS) (1.1); Cervical intraepithelial neoplasia (CIN) grade 1 (1.1); Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1); Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1); Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1); GARDASIL is indicated in boys and men 9 through 26 years of age for; the prevention of the following diseases caused by HPV types included; in the vaccine:; Anal cancer caused by HPV types 16 and 18 (1.2); Genital warts (condyloma acuminata) caused by HPV types 6 and; 11 (1.2); And the following precancerous or dysplastic lesions caused by HPV; types 6, 11, 16, and 18:; Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2); Limitations of GARDASIL Use and Effectiveness:; GARDASIL does not eliminate the necessity for women to; continue to undergo recommended cervical cancer screening.; (1.3, 17); Recipients of GARDASIL should not discontinue anal cancer; screening if it has been recommended by a health care provider.; (1.3, 17); GARDASIL has not been demonstrated to provide protection; against disease from vaccine and non-vaccine HPV types to which; a person has previously been exposed through sexual activity.; (1.3, 14.4, 14.5); GARDASIL is not intended to be used for treatment of active; external genital lesions; cervical, vulvar, vaginal, and anal; cancers; CIN; VIN; VaIN, or AIN. (1.3); GARDASIL has not been demonstrated to protect against; diseases due to HPV types not contained in the vaccine. (1.3,; 14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, and; GARDASIL protects only against those vulvar, vaginal, and anal; cancers caused by HPV 16 and 18. (1.3); GARDASIL does not protect against genital diseases not caused; by HPV. (1.3); Vaccination with GARDASIL may not result in protection in all; vaccine recipients. (1.3); GARDASIL has not been demonstrated to prevent HPV-related; CIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:13 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest that; the efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Human; beings develop a humoral immune response to the vaccine, although the exact mechanism of protection; is unknown.

Drug clinical trials:

Search ClinicalTrials for Adenocarcinoma in Situ

Search NIH Clinical Center for Adenocarcinoma in Situ

Genetic Tests for Adenocarcinoma in Situ

About this section

Anatomical Context for Adenocarcinoma in Situ

About this section

MalaCards organs/tissues related to Adenocarcinoma in Situ:

31
Cervix, Lung, Testes, Colon, Lymph node, Thyroid, Breast, Skin, Ovary, Uterus, Appendix

Animal Models for Adenocarcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

35 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.1EGFR, PAX2, CDKN2A, KRAS, MCM2
2MP:00053919.0EGFR, CDKN2A, KRAS, VIM, PAX2, CDKN1A
3MP:00053709.0CDKN1A, WT1, ESR1, KRAS, EGFR, CDKN2A
4MP:00053678.9WT1, EGFR, CDKN1A, KRAS, ESR1, PAX8
5MP:00053718.9ESR1, ERBB2, KRAS, CDX2, CDKN1A, PGR
6MP:00030128.9PAX8, CDKN1A, CDKN2A, WT1, EGFR, ESR1
7MP:00053908.7ERBB2, CDKN2A, EGFR, CDX2, PGR, CDKN1A
8MP:00053818.5MCM2, ESR1, EGFR, CDKN2A, CDKN1A, CDX2
9MP:00028738.4PGR, MCM2, CDX2, EGFR, WT1, KRAS
10MP:00107718.3CDKN1A, EGFR, CDKN2A, KRAS, MCM2, ERBB2
11MP:00020068.3MCM2, PGR, ESR1, ERBB2, EGFR, CDKN2A
12MP:00053888.2ERBB2, EGFR, WT1, CDKN2A, CDKN1A, VIM
13MP:00053858.1EGFR, WT1, CDKN1A, CDX2, PAX2, PGR
14MP:00053768.0WT1, CDKN2A, EGFR, CDX2, CDKN1A, ERBB2
15MP:00053878.0KRAS, EGFR, WT1, CDKN2A, CDKN1A, VIM
16MP:00053698.0EGFR, CDKN1A, KRAS, WT1, ERBB2, VIM
17MP:00036317.9VIM, ERBB2, CDKN1A, CDKN2A, EGFR, KRAS
18MP:00053897.9PGR, PAX2, PAX8, VIM, ESR1, ERBB2
19MP:00053867.8CDKN2A, CDKN1A, MCM2, PGR, ESR1, VIM
20MP:00053977.7ESR1, MCM7, MCM2, CDKN2A, WT1, EGFR
21MP:00053797.7PGR, KRAS, CDX2, CDKN2A, WT1, CDKN1A
22MP:00053807.4ERBB2, MCM2, VIM, PAX2, EGFR, WT1
23MP:00053787.3MCM2, MCM7, PAX8, ESR1, VIM, ERBB2
24MP:00053846.9CDX2, CDKN1A, MCM7, MCM2, PGR, PAX2
25MP:00107686.9EGFR, PAX8, MCM2, PGR, PAX2, ESR1

Publications for Adenocarcinoma in Situ

About this section

Articles related to Adenocarcinoma in Situ:

(show top 50)    (show all 230)
idTitleAuthorsYear
1
Management of Adenocarcinoma In Situ of the Uterine Cervix: A Comparison of Loop Electrosurgical Excision Procedure and Cold Knife Conization. (25089550)
2014
2
Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4A years after sublobar resection for adenocarcinoma in situ: report of a case. (25377270)
2014
3
High pathologic misdiagnosis of cervical adenocarcinoma in situ. (24475580)
2013
4
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. (23541795)
2013
5
Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases. (22188786)
2012
6
Fertility-sparing treatment in younger women with adenocarcinoma in situ of the cervix. (22030403)
2012
7
Predictive value of negative cone margin status for risk of residual disease among women with cervical adenocarcinoma in situ. (22939281)
2012
8
Using multi-detector-row CT to diagnose ampullary adenoma or adenocarcinoma in situ. (21093190)
2011
9
Cervical adenocarcinoma in situ with negative conization margin: negligible or not? (21607088)
2011
10
Pagetoid adenocarcinoma in situ of the cervix with pagetoid spread into the vagina. (21768854)
2011
11
Risk for residual adenocarcinoma in situ or cervical adenocarcinoma in women undergoing loop electrosurgical excision procedure/conization for adenocarcinoma in situ. (22010519)
2011
12
The safety of conization in the management of adenocarcinoma in situ of the uterine cervix. (21607092)
2011
13
Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. (20423964)
2010
14
Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. (20414103)
2010
15
Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. (19693522)
2010
16
A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. (19188825)
2009
17
Management of atypical glandular cells and adenocarcinoma in situ. (19061821)
2008
18
Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003. (18182979)
2008
19
Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. (18234283)
2008
20
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. (17192788)
2007
21
Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. (16990718)
2006
22
Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization? (17250421)
2006
23
Is improved detection of adenocarcinoma in situ by screening a key to reducing the incidence of cervical adenocarcinoma? (15471248)
2004
24
Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial. (14619639)
2003
25
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. (12468353)
2002
26
Adenocarcinoma in situ of the cervix-controversies in diagnosis and treatment. (17043583)
2001
27
Conservative management of adenocarcinoma in situ of the cervix. (17043589)
2001
28
Atypical glandular cells of undetermined significance in cervical smears after conization. Cytologic features differentiating them from adenocarcinoma in situ. (11284300)
2001
29
Vaginal adenosis with adenocarcinoma in situ in a woman with no recognised antecedent factors. (11284657)
2001
30
Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. (11303584)
2001
31
Adenocarcinoma in situ with a small cell (endometrioid) pattern in cervical smears: a test of the distinction from benign mimics using specific criteria. (10536349)
1999
32
Adenocarcinoma in situ of the cervix: management and outcome. (10366458)
1999
33
Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. (10202666)
1999
34
Comparison of ThinPrep and Pap smear in relation to prediction of adenocarcinoma in situ. (9987454)
1999
35
Adenocarcinoma in situ in Barrett's esophagus with stricture of 10-yr duration: a cytological diagnosis. (8759681)
1996
36
Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. (8684768)
1996
37
Atypical glandular cells of undetermined significance and adenocarcinoma in situ: summoning colposcopic expertise? (8708629)
1996
38
Small-cell neuroendocrine carcinoma of the uterine cervix associated with micro-invasive squamous cell carcinoma and adenocarcinoma in situ. (8870009)
1996
39
Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. (7729727)
1995
40
Adenocarcinoma in situ of the endocervix: human papillomavirus determination by dot blot hybridization and polymerase chain reaction amplification. (8005736)
1994
41
Colposcopy of adenocarcinoma in situ and invasive adenocarcinoma of the cervix. (8332305)
1993
42
A clinicopathological study of adenocarcinoma in situ of the cervix. The influence of cervical HPV infection and other factors, and the role of conservative surgery. (1656927)
1991
43
The topography and invasive potential of cervical adenocarcinoma in situ, with and without associated squamous dysplasia. (2298414)
1990
44
An adenocarcinoma in situ of the uterine cervix that developed into invasive adenocarcinoma after 5 years. (2295444)
1990
45
Cervical adenocarcinoma in situ. (3285263)
1988
46
The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri and related lesions. III. Pitfalls in diagnosis. (3376699)
1988
47
A retrospective review of adenocarcinoma-in-situ and glandular atypia of the uterine cervix. (3040074)
1987
48
Papillary adenocarcinoma in situ of bladder. (4032558)
1985
49
The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri. (266347)
1977
50
Simultaneous adenocarcinoma in situ and epidermoid carcinoma in situ. Report of two cases. (6073902)
1967

Variations for Adenocarcinoma in Situ

About this section

Expression for genes affiliated with Adenocarcinoma in Situ

About this section
Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Pathways for genes affiliated with Adenocarcinoma in Situ

About this section

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 36)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.0CDKN1A, CDKN2A
2
Show member pathways
EGFR-dependent Endothelin signaling events36
9.9KRAS, EGFR
39.7CDKN1A, CDKN2A, EGFR
4
Show member pathways
PLK2 and PLK4 events36
Polo-like kinase signaling events in the cell cycle36
9.7CDKN1A, KRAS, EGFR
59.7EGFR, KRAS, CDKN1A
6
Show member pathways
9.7KRAS, EGFR, ERBB2
7
Show member pathways
9.7KRAS, ERBB2, EGFR
8
Show member pathways
Cell cycle ESR1 regulation of G1 S transition59
Immune response MIF JAB1 signaling59
Cell cycle Cell cycle generic schema 59
9.7ESR1, PGR, CDKN1A
9
Show member pathways
Translation Non genomic rapid action of Androgen Receptor59
9.7ERBB2, EGFR, CDKN1A
109.7EGFR, ERBB2, CDKN1A
11
Show member pathways
Prolactin Signaling Pathway36
Development Prolactin receptor signaling59
Leptin signaling pathway36
9.6KRAS, ERBB2, ESR1
129.6EGFR, WT1, ESR1
139.6EGFR, KRAS, ESR1
14
Show member pathways
Development Ligand independent activation of ESR1 and ESR259
9.6ERBB2, ESR1, EGFR
15
Show member pathways
9.4ERBB2, KRAS, CDKN1A, EGFR
16
Show member pathways
9.4EGFR, ERBB2, KRAS, CDKN1A
17
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
9.4ERBB2, KRAS, EGFR, CDKN1A
189.4ERBB2, KRAS, CDKN1A, EGFR
19
Show member pathways
Signal transduction PTEN pathway59
9.4ERBB2, KRAS, CDKN1A, EGFR
20
Show member pathways
9.4VIM, CDKN1A, EGFR, ERBB2
21
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
9.3KRAS, EGFR, ERBB2, ESR1
22
Show member pathways
9.2ERBB2, KRAS, CDKN1A, CDKN2A, EGFR
23
Show member pathways
Signaling Pathways in Glioblastoma36
9.2EGFR, ERBB2, KRAS, CDKN1A, CDKN2A
24
Show member pathways
9.1CDKN1A, EGFR, ESR1, ERBB2, CDKN2A
259.1KRAS, ESR1, EGFR, ERBB2, CDKN1A
26
Show member pathways
9.0CDKN1A, MCM2, MCM7, CDKN2A
27
Show member pathways
Cell cycle36
9.0MCM2, CDKN1A, CDKN2A, MCM7
289.0PAX8, ERBB2, KRAS, CDKN1A, CDKN2A, EGFR
299.0TOP2A, CDKN1A, MCM7
308.9VIM, CDKN1A, ERBB2, EGFR, KRAS, CDKN2A
31
Show member pathways
8.9VIM, CDKN1A, EGFR, CDKN2A, ERBB2, ESR1
32
Show member pathways
8.8PGR, EGFR, ERBB2, CDKN1A, KRAS, ESR1
33
Show member pathways
8.2CDKN2A, CDKN1A, TOP2A, MCM7, MCM2
34
Show member pathways
8.2CDKN2A, TOP2A, MCM7, MCM2, CDKN1A
358.1WT1, EGFR, KRAS, ERBB2, TOP2A, ESR1

Compounds for genes affiliated with Adenocarcinoma in Situ

About this section

Compounds related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50)    (show all 154)
idCompoundScoreTop Affiliating Genes
1temozolomide44 1110.7VIM, CDKN1A, CDKN2A, EGFR
2anastrozole44 50 1111.6ERBB2, ESR1, EGFR, PGR
3exemestane44 50 60 1112.6EGFR, ERBB2, ESR1, PGR
4lapatinib44 50 1111.6ESR1, ERBB2, EGFR, PGR
5fulvestrant44 50 28 1112.5EGFR, ERBB2, ESR1, PGR
6taxane449.5EGFR, ERBB2, ESR1, PGR, CDKN1A
7letrozole44 50 60 1112.5PGR, EGFR, ERBB2, ESR1
84-hydroxytamoxifen449.4EGFR, ERBB2, VIM, PGR, ESR1
9tetracycline44 1110.4CDKN2A, EGFR, WT1, ERBB2, IFI27
105-aza-2deoxycytidine449.3PGR, CDKN2A, CDKN1A, ESR1, VIM, CDX2
11progestin449.3VIM, ERBB2, PGR, EGFR, ESR1
12geldanamycin44 50 60 1112.2CDKN1A, PGR, ERBB2, EGFR, ESR1
13mucicarmine449.2CEACAM7, CEACAM5, VIM, KRT20
14oxaliplatin44 50 1111.1EGFR, KRAS, CDKN1A, ERBB2, CEACAM5
15leucovorin44 50 1111.1CEACAM5, ERBB2, KRAS, PGR, EGFR
16b 723449.0WT1, VIM, CEACAM5, CEACAM7, KRT20
17irinotecan44 50 1111.0ERBB2, EGFR, CDKN2A, CDKN1A, KRAS, CEACAM5
18retinoid448.9ESR1, PGR, EGFR, VIM, IFI27, CDKN1A
19oligonucleotide448.8IFI27, PAX8, WT1, CDKN2A, CDKN1A, VIM
20tamoxifen44 50 28 1111.8ERBB2, PGR, EGFR, ESR1, CDKN1A, VIM
21rapamycin448.8EGFR, KRAS, ERBB2, IFI27, VIM, CDKN1A
22vitamin d448.8CDKN1A, KRAS, ERBB2, IFI27, ESR1, CDX2
23resveratrol44 60 24 1111.7PGR, ESR1, IFI27, ERBB2, CDKN1A
24agar448.7ERBB2, EGFR, VIM, CEACAM5, PGR, CDKN1A
25cycloheximide448.6VIM, CEACAM7, ERBB2, CDKN1A, CDKN2A, EGFR
26methotrexate50 44 1110.6PGR, ESR1, VIM, ERBB2, TOP2A, CDKN2A
27cytarabine44 50 1110.6CDKN1A, VIM, TOP2A, IFI27, CDKN2A
28chloramphenicol44 1 50 1111.6ESR1, VIM, TOP2A, WT1, CDKN2A, ERBB2
29trastuzumab44 50 1110.5IFI27, TOP2A, ESR1, ERBB2, EGFR, PGR
30docetaxel44 50 60 1111.5CDKN2A, TOP2A, EGFR, CDKN1A, ERBB2, ESR1
31thymidylate448.4ERBB2, TOP2A, IFI27, VIM, CDKN1A, CDKN2A
32butyrate448.2CDKN2A, IFI27, KRAS, CDX2, CDKN1A, CEACAM5
33adriamycin448.2PGR, VIM, TOP2A, CEACAM5, ERBB2, CDKN2A
34p002448.0KRAS, ERBB2, IFI27, TOP2A, CEACAM5
35gefitinib44 50 119.9ERBB2, IFI27, CEACAM7, CEACAM5, VIM, ESR1
36genistein44 28 60 1 24 1112.8EGFR, CDKN1A, ERBB2, IFI27, TOP2A, VIM
37thymidine44 248.7TOP2A, CEACAM5, WT1, CEACAM7, IFI27, CDX2
38paclitaxel44 50 119.6EGFR, CDKN2A, CDKN1A, KRAS, ERBB2, IFI27
39steroid447.6CDX2, CEACAM5, TOP2A, ESR1, PGR, WT1
40cisplatin44 50 60 1110.5ERBB2, EGFR, CDKN2A, CDKN1A, KRAS, IFI27
41testosterone44 60 24 1110.4KRT20, VIM, ESR1, CDKN2A, WT1, EGFR
42serine447.4PAX8, EGFR, ERBB2, KRAS, CDKN1A, WT1
43retinoic acid44 248.3WT1, TOP2A, VIM, CDKN1A, PGR, EGFR
445fluorouracil447.3EGFR, CDKN2A, CDKN1A, KRAS, ERBB2, CEACAM7
45doxorubicin44 50 118.6EGFR, WT1, CDKN2A, CDKN1A, KRT20, ERBB2
46vegf446.4TOP2A, IFI27, KRAS, KRT20, CDKN1A, CDKN2A
47progesterone44 28 60 24 1110.1EGFR, WT1, CDKN2A, CDKN1A, CDX2, KRT20
48tyrosine446.0IFI27, KRT20, IGF2BP3, KRAS, ERBB2, CEACAM5
49paraffin445.7KRAS, ERBB2, IFI27, TOP2A, VIM, ESR1
50estrogen445.3WT1, ESR1, PGR, MCM2, VIM, TOP2A

GO Terms for genes affiliated with Adenocarcinoma in Situ

About this section

Cellular components related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1basolateral plasma membraneGO:00163239.3EGFR, ERBB2, CEACAM5
2MCM complexGO:00425559.2MCM2, MCM7
3nucleolusGO:00057307.5MCM7, MCM2, PAX8, TOP2A, CDX2, CDKN1A
4nucleoplasmGO:00056547.3WT1, MCM7, MCM2, PGR, PAX8, ESR1
5nucleusGO:00056346.0PAX8, PAX2, MCM2, MCM7, IGF2BP3, ESR1

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 48)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of metanephric DCT cell differentiationGO:0200059410.5PAX8, PAX2
2pronephric field specificationGO:003900310.5PAX2, PAX8
3negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesisGO:007230510.5PAX8, PAX2
4negative regulation of apoptotic process involved in metanephric nephron tubule developmentGO:0190021810.5PAX2, PAX8
5negative regulation of apoptotic process involved in metanephric collecting duct developmentGO:0190021510.5PAX2, PAX8
6regulation of metanephric nephron tubule epithelial cell differentiationGO:007230710.5PAX2, PAX8
7negative regulation of mesenchymal cell apoptotic process involved in metanephros developmentGO:0190021210.5PAX8, PAX2
8metanephric nephron tubule formationGO:007228910.5PAX2, PAX8
9metanephric distal convoluted tubule developmentGO:007222110.5PAX2, PAX8
10positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesisGO:007210810.5PAX2, PAX8
11metanephric S-shaped body morphogenesisGO:007228410.4PAX8, WT1
12pronephros developmentGO:004879310.4PAX2, PAX8
13mesenchymal to epithelial transitionGO:006023110.4PAX2, WT1
14mesenchymal to epithelial transition involved in metanephros morphogenesisGO:000333710.4PAX2, PAX8
15metanephric mesenchyme developmentGO:007207510.4PAX2, WT1
16negative regulation of immature T cell proliferation in thymusGO:003308810.4ERBB2, CDKN2A
17mesonephros developmentGO:000182310.3PAX8, PAX2
18metanephric epithelium developmentGO:007220710.3WT1, PAX8, PAX2
19cellular response to gonadotropin stimulusGO:007137110.3PAX8, WT1
20urogenital system developmentGO:000165510.3PAX8, PAX2
21branching involved in ureteric bud morphogenesisGO:000165810.2WT1, PAX8, PAX2
22Ras protein signal transductionGO:000726510.1KRAS, CDKN1A, CDKN2A
23positive regulation of nitric-oxide synthase activityGO:005100010.1KRAS, ESR1
24positive regulation of branching involved in ureteric bud morphogenesisGO:009019010.1PAX8, PAX2
25positive regulation of MAP kinase activityGO:004340610.1EGFR, ERBB2, KRAS
26intermediate filament organizationGO:004510910.1VIM, KRT20
27positive regulation of epithelial cell proliferationGO:005067910.0PAX2, ERBB2, EGFR
28negative regulation of phosphorylationGO:004232610.0CDKN1A, CDKN2A
29positive regulation of fibroblast proliferationGO:004814610.0EGFR, CDKN1A, ESR1
30negative regulation of gene expressionGO:001062910.0CDKN1A, ESR1, PGR
31cellular response to estradiol stimulusGO:007139210.0EGFR, ESR1
32cellular response to epidermal growth factor stimulusGO:007136410.0PAX2, EGFR, MCM7
33negative regulation of cell growthGO:003030810.0CDKN1A, WT1, CDKN2A
34negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:00457369.9CDKN2A, CDKN1A
35positive regulation of protein phosphorylationGO:00019349.9ERBB2, EGFR, KRAS
36fibroblast growth factor receptor signaling pathwayGO:00085439.8ERBB2, KRAS, CDKN1A, EGFR
37positive regulation of transcription, DNA-templatedGO:00458939.8CDKN2A, PAX2, PAX8, CDX2, WT1
38Fc-epsilon receptor signaling pathwayGO:00380959.8EGFR, CDKN1A, ERBB2, KRAS
39DNA unwinding involved in DNA replicationGO:00062689.8MCM7, MCM2
40epidermal growth factor receptor signaling pathwayGO:00071739.8EGFR, CDKN1A, KRAS, ERBB2
41cellular senescenceGO:00903989.7CDKN1A, CDKN2A
42neurotrophin TRK receptor signaling pathwayGO:00480119.7EGFR, CDKN1A, KRAS, ERBB2
43G1/S transition of mitotic cell cycleGO:00000829.5CDKN1A, CDKN2A, MCM2, MCM7
44negative regulation of apoptotic processGO:00430669.3PAX2, EGFR, WT1, CDKN1A, CEACAM5
45phosphatidylinositol-mediated signalingGO:00480159.3EGFR, ERBB2, TOP2A, CDKN1A
46DNA replicationGO:00062608.7MCM7, TOP2A, MCM2
47positive regulation of transcription from RNA polymerase II promoterGO:00459448.6PAX8, PAX2, ESR1, WT1, EGFR, CDKN2A
48mitotic cell cycleGO:00002788.6TOP2A, MCM7, CDKN2A, MCM2, CDKN1A

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1epidermal growth factor-activated receptor activityGO:000500610.1EGFR, ERBB2
2C2H2 zinc finger domain bindingGO:007074210.1WT1, PAX2
3nitric-oxide synthase regulator activityGO:00302359.9EGFR, ESR1
4receptor signaling protein tyrosine kinase activityGO:00047169.8EGFR, ERBB2
5cyclin-dependent protein serine/threonine kinase inhibitor activityGO:00048619.7CDKN2A, CDKN1A
6enzyme bindingGO:00198998.9PGR, ESR1, TOP2A, EGFR
7identical protein bindingGO:00428028.8ESR1, VIM, CEACAM5, ERBB2, EGFR
8DNA bindingGO:00036777.8MCM7, MCM2, PGR, PAX2, PAX8, TOP2A
9protein bindingGO:00055155.2EGFR, IGF2BP3, MCM7, MCM2, PGR, PAX2

Sources for Adenocarcinoma in Situ

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet